The inverse agonist XCT790, which targets estrogen-related receptor alpha (ERRα), was shown to impair mitochondrial activity, leading to a decrease in ACC cell proliferation and promoting cell death both in vitro and in animal models. The gene discussed is ESRRA; the disease is adrenal cortex carcinoma.